Biomarkers as drug development tools: discovery, validation, qualification and use.

Area of Science:

• Biomarker development and regulatory science
• Precision medicine and molecular diagnostics

Background:

• The 21st Century Cures Act (2016) established the Precision Medicine Initiative, driving molecularly-based disease prevention, diagnosis, and treatment.
• Regulatory frameworks by the FDA and EMA now formalize the qualification of drug development tools, including biomarkers.

Purpose of the Study:

• To review the key aspects of biomarker development, from discovery to utilization.
• To provide an understanding of biomarker development processes, their advantages, and limitations.

Main Methods:

• Review of regulatory processes for biomarker qualification.
• Description of biomarker discovery, analytical validation, clinical qualification, and utilization.

Main Results:

• The Act enables formal qualification of biomarkers for drug development, improving clinical trial efficiency.
• Regulatory agencies have established processes for biomarker qualification for companion diagnostics and therapeutic approval.
• Biomarkers for internal trial use (diagnosis, monitoring, stratification) may not require regulatory approval but benefit from qualification.

Conclusions:

• Biomarker development is crucial for advancing precision medicine and molecularly-driven therapeutics.
• Understanding the full lifecycle of biomarker development is essential for appreciating their potential and limitations in clinical practice.